NCT00113217View on ClinicalTrials.gov

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Renal Cell CarcinomaKidney Cancer
Interventions
DRUG

Bevacizumab

10 mg/kg IV on day 1 of each 14-day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00113217 - Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter